SerbiaTuberculosis profile
Population  2014 8.9 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.12 (0.11–0.13) 1.4 (1.3–1.5)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 2.7 (1.2–4.9) 30 (13–55)
Incidence  (includes HIV+TB) 2.1 (1.8–2.4) 24 (21–27)
Incidence (HIV+TB only) 0.017 (0.013–0.021) 0.19 (0.15–0.24)
         
Case detection, all forms (%) 87 (77–99)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.85 (0.31–1.8) 4.7 (1.3–11)
MDR-TB cases among notified pulmonary
TB cases
11 (4–25) 7 (2–16)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 902   81
Pulmonary, clinically diagnosed 432   44
Extrapulmonary 351   8
       
Total new and relapse 1 818    
Previously treated, excluding relapses 14    
Total cases notified 1 832    
Among 1 818 new and relapse cases:
41 (2%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 630 (70%) 54 (37%) 685
Laboratory-confirmed RR-/MDR-TB cases     14
Patients started on MDR-TB treatment ***     13
TB/HIV 2014 Number (%)
TB patients with known HIV status 127 (7)
HIV-positive TB patients 8 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 8 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (78) 1 427
Previously treated cases, excluding relapse, registered in 2013 (69) 49
HIV-positive TB cases, all types, registered in 2013 (84) 19
RR-/MDR-TB cases started on second-line treatment in 2012 (50) 6
XDR-TB cases started on second-line treatment in 2012 (100) 1
Laboratories 2014  
Smear (per 100 000 population) 0.3
Culture (per 5 million population) 16.3
Drug susceptibility testing (per 5 million population) 2.2
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 11
% Funded domestically 92%
% Funded internationally <1%
% Unfunded 7%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-24 Data: www.who.int/tb/data